Global Eosinophilic Esophagitis Drug Market


  • Type: Common Disease Area
  • Published : March 2021
  • Region: Worldwide
  • Country: Other
  • Report ID : 356

  • Format: PPT, PDF

Global Eosinophilic Esophagitis Drug Market Share, Size, Trends, Industry Analysis Report, by Product (Off-Label Drugs, Budesonide Oral Suspension, Fluticasone ODT, Mepolizumab, Reslizumab, Benralizumab, Dupilunab, Omalizumab, QAX576, AKOO2, and Losartan); by Diagnosis; by Treatment; by Regions; Segment Forecast, 2019 – 2028


Report Overview

The global eosinophilic esophagitis drugs market size stood at around USD 120 million in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Eosinophilic esophagitis development is due to the presence of a deficient mucosal barrier in the esophagus and reverse immune reaction causing fissures/lesions, fibrosis, and dysmotility in the esophagus, mediated by Th2 interleukins. Eosinophilic esophagitis is multi-factorial, with around a 7 percent risk of genetic inheritance. Food allergies, and exposure to excessive use of antibiotics, acid suppression, and early life symptoms of gastro-intestinal disorders are also predominant market factors.

Market Drivers

Recently, the potential drug candidates for the treatment of eosinophilic esophagitis have received promising results, which is expected to drive the market forward. In September 2020, Sanofi’s drug candidate Dupixent (dupilumab) received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) to treat eosinophilic esophagitis patients of 12 years and older in collaboration with Regeneron.

Dupixent is the fully human monoclonal antibody that inhibits the signalling of interleukin 4 and 5 proteins, regarded as primary instigators in type 2 inflammations, including EoE. This designation was based on the positive results of part A of phase 3 trials in patients suffering from EoE. Currently, there are no FDA-approved drugs for eosinophilic esophagitis, a progressive type 2 inflammatory disease damaging the functioning of the esophagus.

In the U.S. alone, there are around 160,000 people suffering from eosinophilic esophagitis and are treated with un-approved off label drugs and diet modifications. Among these, around 50,000 have repeated course of treatment. Part A of the phase 3 trial was the randomized, double-blind, placebo-controlled trial in which 81 patients met both primary and secondary endpoint. Enrolled patients were administered with a weekly dose of Dupixent 300 mg over a treatment period of 24-weeks. Patients examined had a reduction in primary symptoms, esophagus inflammation, and reduced eosinophil count on the esophagus mucosal membrane.

Moreover, in August 2019, AstraZeneca announced that FDA has granted orphan drug designation to its drug candidate Fasenra (benralizumab), used in the treatment of EoE. FDA grants this status to drug candidates which are intended to prevent rare disorders/diseases, affecting less than 200,000 individuals in the U.S. market. Drug depletes eosinophils present in both blood and connective tissue during eosinophilic esophagitis treatment and is undergoing clinical trials to test its specificity and efficacy. Currently, there are no FDA-approved drugs for eosinophilic esophagitis treatment, so there is a race among market players to have a first-mover advantage.

1. Global Eosinophilic Esophagitis Drug Market Overview………………………….
A. Market Size
2. Market Growth Drivers……………………………………………………..………….
A. Growing Cases of Digestive Tract Inflammatory Diseases
B. Increased Allergy in Esophagus, Accumulation of Eosinophils, Dysphagia & Impaction in Esophagus
C. Increasing Population
D. Lowering of Immunity
E. Advancement in Novel Treatment
3. Five Force Analysis.……………………………………………………………………
A. Threat of New Entrants
B. Bargaining Power of Buyers/Consumers
C. Bargaining Power of Suppliers
D. Threat of Substitute Products
E. Intensity of Competitive Rivalry
4. Eosinophilic Esophagitis Drug Market Segmentation……………..………….
A. By Type
I. Budesonide
II. Fluticasone
III. Others
B. By Application
I. Hospitals
II. Clinics
III. Drugstores
C. By Geography
I. North America Market Analysis
II. Europe Market Analysis
III. Asia-Pacific Market Analysis
IV. Latin America, Middle-East and Africa Market Analysis
5. Eosinophilic Esophagitis Major Drugs Market Share……………………………
A. Key Findings
B. Market Analysis, Insights and Forecast to 2028
6. Competitive Landscape………………………………………………………….………
A. Major Players
B. Products in Pipeline
7. Key Company Profiles…………………………………………………………………….
A. AstraZeneca Company overview, Product & Services, Strategies & Financials
B. GSK Company overview, Product & Services, Strategies & Financials
C. Bayer Company profile, Product & Services, Strategies & Financials
8. Potential Growth Opportunities…………………………………………..…………
A. Advancements in drug development
B. Untapped markets in developing economies
9. Factors Driving Future Growth………………………………………………………
A. Key Industry Trends and Recent Developments in Eosinophilic Esophagitis Drugs Market
B. Future Opportunities
10. Conclusion

Market Segmentation

By Treatment:

Based on the treatment, the global eosinophilic esophagitis drug market is bifurcated into dietary therapy, medication, dilation, others. In 2020, the dietary therapy market segment accounted for the largest share, among all. This high market segment share is due to unmet needs, for instance, the natural history of food sensitization and associated reactions in eosinophilic esophagitis patients, is still not clear. Study shows that less than 10 percent of kids regain their ability to have all kinds of food, previously being eliminated from their routine diet. However, clinical characteristics that align with food being introduced remain elusive and there are not any predictive indexes for its success or failure.

Moreover, current allergy testing for the food triggers in eosinophilic esophagitis has variable results, depending on test type and food being tested. In kids, the combined patch-based diets and skin prick have a moderate success rate of 50-60 percent, however, in adults, these tests show a very low success ratio to predict allergic food triggers. Many questions still to be ascertained in EoE, including a proof for antigen-specific T cells, and the timing of immunologic shift during food reaction from innate to adaptive immunity. Such questions in combination with the impact of food triggers in EoE drives the need for new allergy testing tests for EoE.

By Product:

Based on the product, the eosinophilic esophagitis drug market is categorized into off-label drugs, budesonide oral suspension, fluticasone ODT, Mepolizumab, Reslizumab, Benralizumab, Dupilunab, Omalizumab, QAX576, AKOO2, and Losartan. In 2020, the Dupilunab market segment accounted for the largest revenue share. Dupixent is the fully human monoclonal antibody that inhibits the signalling of interleukin 4 and 5 proteins, regarded as primary instigators in type 2 inflammations, including EoE. This designation was based on the positive results of part A of phase 3 trials in patients suffering from eosinophilic esophagitis.

By Region:

Geographically, the market is segregated as North America, Asia Pacific, Europe, South America, and Middle East & Africa. North America market is the largest regional revenue contributor followed by Europe and the Asia Pacific market. The competition among market players to have first-mover advantage, as there is no FDA approved drug for EoE and rising economic burden. In the U.S. alone, around 160,000 people are suffering from eosinophilic esophagitis and are treated with un-approved off label drugs and diet modifications. The annual healthcare burden of EoE in the U.S. alone costs about USD 1.4 billion.

Several dedicated associations and academic institutions such as Rare Diseases Clinical Research Network (CEGIR) and the American Partnership for Eosinophilic Disorders (APFED), particularly in developed economies are responsible for providing research grants and funding. For instance, in 2020, the American Academy of Allergy, Asthma & Immunology (AAAAI) and APFED awarded a grant of USD 140,000 for two years to study how the immune system interacts with food allergy substances causing the onset of EoE in patients. The research will also contribute to identifying new targets for drug development and disease pathogenesis.

Moreover, Joshua B. Wechsler, the assistant professor at the North-western University Feinberg School of Medicine received a research grant of USD 100,000 for 2020-21, for its project to understand the role of mast cells in eosinophilic esophagitis, endoscopic abnormalities, and the impact of possible treatment. The project would analyse novel pathways from biopsies and understand the interactions of mast cells and associated mediators.

Key Industry Players

The prominent market players operating are Regeneron Pharmaceuticals, Adare Pharmaceuticals, Inc., Bristol-Myers Squibb, Takeda (Shire), DBV Technologies, Dr. Falk Pharma GmbH, Allakos, Inc., Arena Pharmaceuticals, and Ception Therapeutics.

In September 2020, the U.S.-based private equity firm TPG Capital announced the establishment of a new firm “Ellodi Pharmaceuticals” in the market. The new company will be dedicated to the clinical development of APT-1011, a novel candidate for the treatment of EoE, spun out from Adare Pharmaceuticals. APT-1011 is currently into phase 3 (FLUTE II) study.

Research Methodology

Insights10 will provide you reports within 10 key parameters which are:

  1. Market overview
  2. Market growth drivers & restraints
  3. Epidemiology or disease type
  4. Market segmentation
  5. Market share
  6. Competitive landscape
  7. Key company profiles
  8. Healthcare policies & regulatory framework
  9. Reimbursement scenario
  10. Factors driving future growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision making for business stakeholders. Our focused approach to develop reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

Our analysis methodology involves three critical stages:

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers and researchers across countries through which we engage with local experts to gather key data points and assumptions around each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain the high level of accuracy and consistency. The market data is analysed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, market share as well as segment-level analysis of the specific market. Our report includes precise, to the point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

  • Statistical Databases
  • Company Websites/Annual Reports
  • Trade Publications
  • Online Databases
  • Published Research Reports
  • Whitepapers
  • Press Releases of Key Market Players

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameter and micro indicators. The macro parameters includes changes in government policies, demand and supply of the market, government intervention programs and major market share. The micro indicators GDP growth, market size, market volume etc. We also understand nuances specific to each country like US, Canada, India, Germany, etc. and have worked across 60+ countries and hence no only understand global trends, but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. start with large overall market and segment different areas and bottom-up approach i.e. start with population and epidemiology and roll up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach mainly used for new product forecasting and bottom-up approach is used for demand estimation of any product for different countries summed up to form total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and Africa for the period of 2020 to 2028. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape and policy and regulatory scenario and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases and the company level averages etc.

We make sure to finalize the numbers in alignment to the market research. Firstly, our internal experts ensure thorough validation and checking to ensure the accurate and precise analysis and then validation is also done using multiple data analysis model.  Two level validation is done and entails finalization of report scope and to way of representation pattern.

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analysed and synthesized. A second series of interviews are done if necessary to check and validate. The future opportunities are analysed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results are then, interpreted by considering following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue / volume
  • Analyzing current needs and determining penetration to estimate market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and its impact to the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumptions.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy this report, please complete the form below.

    We value your inquiry and offer free customization with every report to fulfil your exact research needs.

    This website is secure and your personal details are safe.

    This report addresses

    • Market intelligence to enable effective decision making
    • Growth opportunities and trend analysis
    • Competitive benchmarking
    • Historical data & forecasts
    • Regional opportunities

    Need more?

    • Speak to our analyst to know how this research was put together
    • Add more countries or regions as part of customisation
    • Understand how this report can have direct impact on your revenue

    Get a custom report based on your requirements